BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 28939847)

  • 21. Schedule-dependent interaction between temsirolimus and cetuximab in head and neck cancer: a preclinical study.
    Lattanzio L; Milano G; Monteverde M; Tonissi F; Vivenza D; Merlano M; Lo Nigro C
    Anticancer Drugs; 2016 Jul; 27(6):533-9. PubMed ID: 26982238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
    Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
    Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibition of radiation induced migration of human head and neck squamous cell carcinoma cells by blocking of EGF receptor pathways.
    Pickhard AC; Margraf J; Knopf A; Stark T; Piontek G; Beck C; Boulesteix AL; Scherer EQ; Pigorsch S; Schlegel J; Arnold W; Reiter R
    BMC Cancer; 2011 Sep; 11():388. PubMed ID: 21896192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Monitoring of circulating tumor cells and their expression of EGFR/phospho-EGFR during combined radiotherapy regimens in locally advanced squamous cell carcinoma of the head and neck.
    Tinhofer I; Hristozova T; Stromberger C; Keilhoiz U; Budach V
    Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e685-90. PubMed ID: 22583603
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of epithelial-mesenchymal transition by cetuximab via the EGFR-GEP100-Arf6-AMAP1 pathway in head and neck cancer.
    Matsumoto Y; Sakurai H; Kogashiwa Y; Kimura T; Matsumoto Y; Shionome T; Asano M; Saito K; Kohno N
    Head Neck; 2017 Mar; 39(3):476-485. PubMed ID: 27880014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hedgehog signaling alters reliance on EGF receptor signaling and mediates anti-EGFR therapeutic resistance in head and neck cancer.
    Keysar SB; Le PN; Anderson RT; Morton JJ; Bowles DW; Paylor JJ; Vogler BW; Thorburn J; Fernandez P; Glogowska MJ; Takimoto SM; Sehrt DB; Gan GN; Eagles-Soukup JR; Serracino H; Hirsch FR; Lucia MS; Thorburn A; Song JI; Wang XJ; Jimeno A
    Cancer Res; 2013 Jun; 73(11):3381-92. PubMed ID: 23576557
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phase 1 study of EGFR-antisense DNA, cetuximab, and radiotherapy in head and neck cancer with preclinical correlatives.
    Bauman JE; Duvvuri U; Thomas S; Gooding WE; Clump DA; Karlovits B; Wehbe A; Miller FR; Kim S; Sen M; Heron DE; Grandis JR; Argiris A
    Cancer; 2018 Oct; 124(19):3881-3889. PubMed ID: 30291796
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combined cetuximab and celecoxib treatment exhibits a synergistic anticancer effect on human oral squamous cell carcinoma in vitro and in vivo.
    Qian M; Qian D; Jing H; Li Y; Ma C; Zhou Y
    Oncol Rep; 2014 Oct; 32(4):1681-8. PubMed ID: 25328959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ErbB activation signatures as potential biomarkers for anti-ErbB3 treatment in HNSCC.
    Alvarado D; Ligon GF; Lillquist JS; Seibel SB; Wallweber G; Neumeister VM; Rimm DL; McMahon G; LaVallee TM
    PLoS One; 2017; 12(7):e0181356. PubMed ID: 28723928
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
    Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
    Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Novel EGFR ectodomain mutations associated with ligand-independent activation and cetuximab resistance in head and neck cancer.
    Nair S; Trummell HQ; Rajbhandari R; Thudi NK; Nozell SE; Warram JM; Willey CD; Yang ES; Placzek WJ; Bonner JA; Bredel M
    PLoS One; 2020; 15(2):e0229077. PubMed ID: 32069320
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models.
    Stegeman H; Kaanders JH; van der Kogel AJ; Iida M; Wheeler DL; Span PN; Bussink J
    Radiother Oncol; 2013 Mar; 106(3):383-9. PubMed ID: 23453541
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epithelial-mesenchymal-transition induced by EGFR activation interferes with cell migration and response to irradiation and cetuximab in head and neck cancer cells.
    Holz C; Niehr F; Boyko M; Hristozova T; Distel L; Budach V; Tinhofer I
    Radiother Oncol; 2011 Oct; 101(1):158-64. PubMed ID: 21665310
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Disruption of the HER3-PI3K-mTOR oncogenic signaling axis and PD-1 blockade as a multimodal precision immunotherapy in head and neck cancer.
    Wang Z; Goto Y; Allevato MM; Wu VH; Saddawi-Konefka R; Gilardi M; Alvarado D; Yung BS; O'Farrell A; Molinolo AA; Duvvuri U; Grandis JR; Califano JA; Cohen EEW; Gutkind JS
    Nat Commun; 2021 Apr; 12(1):2383. PubMed ID: 33888713
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antitumor Effects of MEHD7945A, a Dual-Specific Antibody against EGFR and HER3, in Combination with Radiation in Lung and Head and Neck Cancers.
    Li C; Huang S; Armstrong EA; Francis DM; Werner LR; Sliwkowski MX; van der Kogel A; Harari PM
    Mol Cancer Ther; 2015 Sep; 14(9):2049-59. PubMed ID: 26141946
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma.
    Shimizu R; Ibaragi S; Eguchi T; Kuwajima D; Kodama S; Nishioka T; Okui T; Obata K; Takabatake K; Kawai H; Ono K; Okamoto K; Nagatsuka H; Sasaki A
    Int J Oncol; 2019 Jan; 54(1):283-294. PubMed ID: 30431077
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selective inhibition of PI3K110α as a novel therapeutic strategy for cetuximab‑resistant oral squamous cell carcinoma.
    Tsuchihashi H; Naruse T; Yanamoto S; Okuyama K; Furukawa K; Omori K; Umeda M
    Oncol Rep; 2020 Sep; 44(3):863-872. PubMed ID: 32705230
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Altered binding avidities and improved growth inhibitory effects of novel anti-HER3 mAb against human cancers in the presence of HER1-or HER2-targeted drugs.
    Okita K; Imai K; Kato K; Sugiura R; Endo Y; Masuko K; Tomioka Y; Masuko T
    Biochem Biophys Res Commun; 2021 Oct; 576():59-65. PubMed ID: 34482024
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
    Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
    Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ASCT2 (SLC1A5) is an EGFR-associated protein that can be co-targeted by cetuximab to sensitize cancer cells to ROS-induced apoptosis.
    Lu H; Li X; Lu Y; Qiu S; Fan Z
    Cancer Lett; 2016 Oct; 381(1):23-30. PubMed ID: 27450723
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.